TriangleNCT02354534 · OUTCOME
Viral Clearance of HPV
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- 41 weeks
What was measured
Number of participants whose human papillomavirus (HPV) genotypes present at study entry become undetectable without surgical intervention. HPV genotyping detects strains of HPV present at each timepoint. For this outcome, we evaluated whether strains of HPV detected at study entry became undetectable during the study participation.
Analysis population: Subjects enrolled in the study who received at least one dose of the investigational drug, and on whom we have outcomes data. 2 participants did not have data collected for this outcome.
Groups in this outcome
50 mg Artesunate Suppositories, 1 Cycle
Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated). Artesunate Suppositories
200 mg Artesunate Suppositories, 1 Cycle
Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated). Artesunate Suppositories
200 mg Artesunate Suppositories,2 Cycles
Subjects enrolled in this cohort will receive 2 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated). Artesunate Suppositories
200 mg Artesunate Suppositories,3 Cycles
Subjects enrolled in this cohort will receive 3 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated). Artesunate Suppositories
| Group | Source count |
|---|---|
| 50 mg Artesunate Suppositories, 1 Cycle | 3 |
| 200 mg Artesunate Suppositories, 1 Cycle | 9 |
| 200 mg Artesunate Suppositories,2 Cycles | 8 |
| 200 mg Artesunate Suppositories,3 Cycles | 8 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| 50 mg Artesunate Suppositories, 1 Cycle | 1 | Not reported | Not reported | Not reported | Not reported |
| 200 mg Artesunate Suppositories, 1 Cycle | 3 | Not reported | Not reported | Not reported | Not reported |
| 200 mg Artesunate Suppositories,2 Cycles | 4 | Not reported | Not reported | Not reported | Not reported |
| 200 mg Artesunate Suppositories,3 Cycles | 1 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 4
- group Id
- OG003
- value
- 1
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 9
- group Id
- OG002
- value
- 8
- group Id
- OG003
- value
- 8
- units
- Participants
- description
- Number of participants whose human papillomavirus (HPV) genotypes present at study entry become undetectable without surgical intervention. HPV genotyping detects strains of HPV present at each timepoint. For this outcome, we evaluated whether strains of HPV detected at study entry became undetectable during the study participation.
- groups
- description
- Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated). Artesunate Suppositories
- id
- OG000
- title
- 50 mg Artesunate Suppositories, 1 Cycle
- description
- Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated). Artesunate Suppositories
- id
- OG001
- title
- 200 mg Artesunate Suppositories, 1 Cycle
- description
- Subjects enrolled in this cohort will receive 2 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated). Artesunate Suppositories
- id
- OG002
- title
- 200 mg Artesunate Suppositories,2 Cycles
- description
- Subjects enrolled in this cohort will receive 3 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated). Artesunate Suppositories
- id
- OG003
- title
- 200 mg Artesunate Suppositories,3 Cycles
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Subjects enrolled in the study who received at least one dose of the investigational drug, and on whom we have outcomes data. 2 participants did not have data collected for this outcome.
- reporting Status
- POSTED
- time Frame
- 41 weeks
- title
- Viral Clearance of HPV
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice